Published

In vitro and in vivo metabolism of psilocybin’s active metabolite psilocin

An abstract is available from the original source but is not redistributed by this tracker. Read the source record.

Open source BibTeX RIS

Bibliographic context

Journal: Frontiers in Pharmacology
Date: 2024-04-29
Source: Crossref
DOI: 10.3389/fphar.2024.1391689
PubMed: 38741590

Authors

Thomann Jan Kolaczynska Karolina E.Stoeckmann Oliver V.Rudin Deborah Vizeli Patrick Hoener Marius C.Pryce Christopher R.Vollenweider Franz X.Liechti Matthias E.Duthaler Urs

Watch author

Derived topics and classifications

psilocybin psilocin Pharmacology Mechanism of Action Receptor Pharmacology Clinical Trial Animal Study In Vitro Study Drug Interactions Clinical Trial

Citation graph

40 referenced DOIs found in stored source metadata. 12 indexed papers cite this DOI.

Open citation network

10.1002/cpt.2487 10.1002/dta.3668 10.1111/j.1476-5381.1960.tb00290.x 10.3389/fphar.2018.00100 10.1038/s41598-017-13282-7 10.1111/cts.12692 10.1038/clpt.2011.287 10.1080/03602532.2016.1278228 10.1080/00498254.2023.2278488 10.1038/sj.clpt.6100406 10.1520/jfs15014j 10.1177/0269881116675513

Indexed papers citing this DOI

Contribution of the Serotonin 5-HT2A Receptor to the Therapeutic Effect of Psilocin on Social Behavior Deficits in Mice Repeatedly Exposed to Social Defeat Stress2026-09-01 Psilocybin-Assisted Therapy in Psychiatry: A Narrative Clinical Review of Mechanisms, Therapeutic Applications, and Emerging Evidence (2025-2026)2026-08-12 Cardiovascular safety of psilocybin in psychiatric practice: a narrative review2026-08-01 Studies on enzymatic hydrolysis of psilocin- O -glucuronide for screening of psilocin in human urine by liquid chromatography-triple quadrupole tandem mass spectrometry2026-06-04 Psilocin glucuronide in whole blood: a stable and useful biomarker of psilocybin intake2026-05-23 The magic of mushrooms: psilocybin influences behavior in the mangrove rivulus fish, Kryptolebias marmoratus2026-05-07 Synthesis and Characterization of Psilocybin Metabolites and Deuterated Analogs2026-03-18 Design, Synthesis, and Pharmacokinetic Profiling of Fluorinated Reversible N -Alkyl Carbamate Derivatives of Psilocin for Sub-Hallucinogenic Brain Exposure2026-02-12 Development of a PBPK model of psilocybin/psilocin from Psilocybe cubensis (magic mushroom) in mice, rats, and humans2025-04-21 Psilocin, A Psychedelic Drug, Exerts Anticonvulsant Effects Against PTZ- and MES-Induced Seizures in Mice via 5-HT1A and CB1 Receptors: Involvement of Nitrergic, Opioidergic, and Kynurenine Pathways2025-04-01 Elucidating the Phase I metabolism of psilocin in vitro2025-03-01 In vitro and in vivo metabolism of psilocybin’s active metabolite psilocin2024-04-29

Related papers

The Therapeutic Potential of Psilocybin in Anorexia Nervosa in Young AdultsClinicalTrials.gov · 2026-08-14 Neurobiological Effects of Psilocybin in Treatment Resistant Bipolar Depression: An Emotional-Processing fMRI Pilot StudyClinicalTrials.gov · 2026-08-10 An Examination of Psilocybin Effects on Biomarkers of Longevity, Healthy Aging, and Purpose in LifeClinicalTrials.gov · 2026-08-17 PRISMatic: A Phase 1b Randomized, Double-Armed, Parallel-Group, Placebo-Controlled Trial of Psilocybin Efficacy With or Without Pimavanserin PretreatmentClinicalTrials.gov · 2026-07-21 A Randomized, Double-Blind, Single Ascending Dose Study to Identify a Safe and Non-Psychedelic Dose of PsilocybinClinicalTrials.gov · 2026-07-17 PSilocybin Microdose for psYCHological and Existential Distress in PALliative Care (PSYCHED-PAL): A Multi-site Phase 3 Double-blind, Placebo-controlled, Parallel-arm Clinical TrialClinicalTrials.gov · 2026-07-10 PSilocybin for psYCHological and Existential Distress in PALliative Care (PSYCHED-PAL): A Multi-site, Open-label, Single Arm Phase I/II Proof-of-concept, Dose-finding, and Feasibility Clinical TrialClinicalTrials.gov · 2026-07-10 5-HT2A Agonist Psilocybin in the Treatment of Tobacco Use DisorderClinicalTrials.gov · 2026-06-29